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Abstract Objective: To systemat-
ically review the medical literature on
the association between glucose var-
iability measures and mortality in
critically ill patients. Meth-
ods: Studies assessing the
association between a measure of
glucose variability and mortality that
reported original data from a clinical
trial or observational study on criti-
cally ill adult patients were searched
in Ovid MEDLINE
 and Ovid EM-
BASE
. Data on patient populations,
study designs, glucose regulations,
statistical approaches, outcome mea-
sures, and glucose variability
indicators (their deﬁnition and appli-
cability) were extracted.
Result: Twelve studies met the
inclusion criteria; 13 different indi-
cators were used to measure glucose
variability. Standard deviation and
the presence of both hypo- and
hyperglycemia were the most com-
mon indicators. All studies reported a
statistically signiﬁcant association
between mortality and at least one
glucose variability indicator. In four
studies both blood glucose levels and
severity of illness were considered as
confounders, but only one of them
checked model assumptions to assert
inference validity. Conclu-
sions: Glucose variability has been
quantiﬁed in many different ways,
and in each study at least one of them
appeared to be associated with mor-
tality. Because of methodological
limitations and the possibility of
reporting bias, it is still unsettled
whether and in which quantiﬁcation
this association is independent of
other confounders. Future research
will beneﬁt from using an indicator
reference subset for glucose variabil-
ity, metrics that are linked more
directly to negative physiological
effects, more methodological rigor,
and/or better reporting.
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Introduction
Glucose control aiming at normoglycemia, i.e., blood
glucose levels (BGLs) of 80–110 mg/dl, which is fre-
quently referred to as ‘‘tight glycemic control’’ (TGC),
decreased morbidity and mortality of critically ill patients
[1]. Later studies investigated the effect of various forms
of glucose control on mortality and morbidity and
reported that no beneﬁcial effects of these interventions
were found [2–5]. Some studies showed that their
implementation of glucose control with insulin comes
with the risk of hypoglycemia [6, 7], others did not [8, 9].
Intensive Care Med (2011) 37:583–593
DOI 10.1007/s00134-010-2129-5 REVIEWPartly in order to reconcile the ﬁndings of these seem-
ingly contradictory results, confounders—correlating with
both blood glucose levels and mortality—and other pos-
sible factors associated with mortality were sought. One
of these potential confounders or possible factors associ-
ated with mortality is blood glucose variability, which in
essence quantiﬁes the spread in a set of blood glucose
levels.
The underlying idea for considering glucose variabil-
ity is that it, similar to hyperglycemia, can be associated
with mortality by increasing oxidative stress, neuronal
damage, mitochondrial damage, and coagulation activity
[10–13]. It has been shown that rapid ﬂuctuations of
BGLs increase oxidative stress and are more detrimental
than sustained hyperglycemia. In consequence, investi-
gating the role of blood glucose variability as a new target
in blood glucose control was suggested [13, 14]. How-
ever, one may distinguish between various sources of
variability in BGLs. The variability can be relatively
controllable, induced by intervention, or its can effec-
tively appear random (e.g., due to patient condition
changes). All variability that exposes the patient to neg-
ative physiological consequences is to be avoided.
The main objective of this systematic review was to
identify and summarize published studies on glucose
variability and their association with mortality in criti-
cally ill patients. This summary includes an overview of
all the glucose variability indicators used along with a
methodological examination of the studies. This review
may form a basis for future developments of a standard
list of well-deﬁned glucose variability indicators and
methodological considerations thereby contributing to the
comparability and quality of new studies.
Materials and methods
We searched for relevant English-language articles based
on keywords in title, abstract, and MeSH terms, using
Ovid MEDLINE
, Ovid MEDLINE
 In-Process (1950 to
April 30, 2010) and Ovid EMBASE
 (1980 to April 30,
2010). The ﬁnal literature search was performed on May
10, 2010.
Figure 1 shows the search strategy. Searching was
supplemented by scanning bibliographies from identiﬁed
articles. Two authors independently examined all titles
and abstracts. Discrepancies among the two authors were
resolved by consensus involving a third author. Articles
were included if they reported original data from a clin-
ical trial or observational study on critically ill patients
and concerned the association between glucose variability
and mortality. Opinion papers, surveys, and letters were
excluded.
From the selected papers, the same two authors
extracted data on the patient population, study design,
glucose regulation, statistical approach, outcome mea-
sures, and glucose variability indicators (their deﬁnition
and applicability). Discrepancies between the two authors
were again resolved by consensus after involving the
Fig. 1 The search ﬂow diagram
584same third author. Heterogeneity of the retrieved studies
in terms of the extracted data (patient populations, study
designs, variability indicators etc.) was informally asses-
sed to determine whether a meta-analysis was justiﬁed.
Results
Searching the online databases resulted in 135 articles.
Initial screening of titles and abstracts rendered 22 articles
eligible for further full-text review. Inspecting the bibli-
ographies of these articles yielded an extra article. On the
basis of the full-text review, 11 studies, including the one
added by the bibliographic search, were excluded, leaving
12 articles for detailed analysis. Table 1 uniformly
describes these studies.
Table 2 lists and describes the 13 glucose variability
indicators used. The most frequently used indicator was
the standard deviation (SD) of BGLs per patient, which
was employed in 6 out of 12 articles. Five out of six
studies reported on a statistically signiﬁcant positive
association between SD and mortality. The populations in
these studies were sepsis patients (2/6) and mixed surgical
and medical patients (4/6).
The second commonly used indicator is what we call
the ‘‘hyper–hypo’’ indicator which is a binary (true or
false) variable deﬁned as true for a patient having both
hyperglycemia and hypoglycemia measurements during
some predeﬁned interval. Two interval-variants of the
hyper–hypo indicator were encountered in 3/12 studies:
one variant was deﬁned for the whole intensive care unit
(ICU) admission and the other for the ﬁrst 24 h after
admission. Two of the three studies using the hyper–hypo
indicator showed a statistically signiﬁcant association
with mortality and the third study reported consistent but
non-signiﬁcant association. However, six different
thresholds were used in these three studies for deﬁning
hyperglycemia ([150, [180, and [216 mg/dl) and
hypoglycemia (\60, \72, and \81 mg/dl). The study
populations were also different in these studies and
included patients with brain injury, mixed medical/sur-
gical patients, and non-diabetic patients receiving insulin
during their admission.
Each of the rest of the eleven indicators was used in
only one study. All of them were found to be statistically
signiﬁcantly associated with ICU and/or hospital
mortality.
In the majority of studies the association between
mortality and the used variability indicator was adjusted
for by using linear logistic regression analysis (Table 1).
However, different sets of possible confounders were
used. Six out of 12 studies used at least one severity of
illness indicator as a confounder in the ﬁnal regression
model. Only four studies included the mean or median
BGL as a confounder in the ﬁnal regression model. In
four studies both blood glucose levels and severity of
illness were considered as confounders. All studies
assumed a linear relationship between (log odds of)
mortality and either the blood glucose variability indica-
tor itself or the confounders used, but only one study
reported on testing this assumption [15]. A more recent
study [16] showed that observed mortality reduction with
intensive insulin therapy (IIT) in the original Leuven
trials could not be attributed to blood glucose variation
deﬁned by SD and mean daily d blood glucose. However
that study also showed that increased blood glucose var-
iation was associated with mortality irrespective of blood
glucose level. Protocol implementation (with or without
IIT) and level of adherence to it either were not men-
tioned or differed from one study to another. In addition,
different BGL target ranges were used in the studies that
reported on adherence.
Discussion
The apparent heterogeneity of the retrieved studies does
not justify conducting a meta-analysis. Although all 12
studies reported a signiﬁcant association between mor-
tality and one or more of a set of 13 glucose variability
indicators, the study heterogeneity, the methodological
limitations, and the possibility of reporting bias do not
support an unequivocal evidence for the independence of
this association of other factors, let alone its causal nature.
To our knowledge, this is the ﬁrst review of the literature
on the association between blood glucose variability and
mortality. Because of the current attention to blood glu-
cose variability in critically ill patients, we believe the
review to be timely, enabling the dissemination of the
lessons learned from the reviewed studies. A limitation of
our search is that we only addressed studies that had a
main objective of evaluating the association between
mortality and glucose variability; we might have missed
some studies with a limited focus.
Aside from differences in patient case-mix and in the
associated therapy, the diversity of the variability indi-
cators used, and the fact that only few if at all were used
together, hampers comparability of the studies and hence
of the consolidation of evidence. In addition, and espe-
cially because none of the studies had an randomized
control trial (RCT) design, one cannot a priori exclude the
possibility of a reporting bias, in which only indicators
showing associations in a study were reported.
BGL distributions are not necessarily normally dis-
tributed nor even symmetric about the mean, especially as
the physiologically reported variations are also not nec-
essarily normally distributed. Yet, many studies report
variability in terms of, e.g., standard deviation. Inference
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n
c
l
u
s
i
o
n
B
a
g
s
h
a
w
e
t
a
l
.
[
2
6
]
,
2
0
0
9
,
A
u
s
t
r
a
l
i
a
,
N
e
w
Z
e
a
l
a
n
d
6
6
,
1
8
4
p
a
t
i
e
n
t
s
,
ﬁ
r
s
t
2
4
h
o
f
a
d
m
i
s
s
i
o
n
,
2
4
I
C
U
s
H
y
p
e
r
–
h
y
p
o
I
C
U
a
n
d
h
o
s
p
i
t
a
l
m
o
r
t
a
l
i
t
y
W
h
o
l
e
b
l
o
o
d
s
a
m
p
l
i
n
g
\
1
0
%
o
f
p
a
t
i
e
n
t
s
w
i
t
h
I
I
T
p
r
o
t
o
c
o
l
U
n
i
v
a
r
i
a
t
e
a
n
a
l
y
s
i
s
a
n
d
m
u
l
t
i
v
a
r
i
a
t
e
l
o
g
i
s
t
i
c
r
e
g
r
e
s
s
i
o
n
a
d
j
u
s
t
e
d
f
o
r
I
C
U
l
o
c
a
t
i
o
n
,
a
g
e
,
s
e
x
,
c
o
-
m
o
r
b
i
d
i
t
y
,
n
o
n
a
g
e
r
e
l
a
t
e
d
A
P
A
C
H
E
I
I
,
s
u
r
g
i
c
a
l
s
t
a
t
u
s
,
p
r
i
m
a
r
y
d
i
a
g
n
o
s
i
s
,
M
V
,
a
c
u
t
e
k
i
d
n
e
y
i
n
j
u
r
y
,
a
n
d
y
e
a
r
B
G
v
a
r
i
a
b
i
l
i
t
y
w
a
s
a
s
s
o
c
i
a
t
e
d
w
i
t
h
g
r
e
a
t
e
r
o
d
d
s
o
f
a
d
j
u
s
t
e
d
I
C
U
(
1
.
5
,
9
5
%
C
I
1
.
4
–
1
.
6
)
a
n
d
h
o
s
p
i
t
a
l
(
1
.
4
,
9
5
%
C
I
1
.
3
–
1
.
5
)
m
o
r
t
a
l
i
t
y
,
w
h
e
n
c
o
m
p
a
r
e
d
w
i
t
h
h
y
p
o
g
l
y
c
e
m
i
a
a
l
o
n
e
E
a
r
l
y
v
a
r
i
a
b
i
l
i
t
y
i
n
B
G
i
s
r
e
l
a
t
i
v
e
l
y
c
o
m
m
o
n
a
n
d
i
n
d
e
p
e
n
d
e
n
t
l
y
p
o
r
t
e
n
d
s
a
n
i
n
c
r
e
a
s
e
d
r
i
s
k
f
o
r
m
o
r
t
a
l
i
t
y
P
i
d
c
o
k
e
e
t
a
l
.
[
2
7
]
,
2
0
0
9
,
U
S
4
9
p
a
t
i
e
n
t
s
w
i
t
h
s
e
v
e
r
e
b
u
r
n
s
T
h
e
p
e
r
c
e
n
t
e
x
c
u
r
s
i
o
n
a
b
o
v
e
a
n
d
b
e
l
o
w
t
a
r
g
e
t
M
o
r
t
a
l
i
t
y
F
i
n
g
e
r
c
a
p
i
l
l
a
r
y
s
a
m
p
l
i
n
g
N
u
r
s
e
d
r
i
v
e
n
W
i
t
h
p
r
o
t
o
c
o
l
T
R
8
0
–
1
1
0
M
1
h
U
n
i
v
a
r
i
a
t
e
a
n
a
l
y
s
i
s
I
n
d
i
v
i
d
u
a
l
a
v
e
r
a
g
e
v
a
r
i
a
b
i
l
i
t
y
w
a
s
5
0
±
8
%
.
P
e
r
c
e
n
t
e
x
c
u
r
s
i
o
n
s
i
n
t
h
o
s
e
w
i
t
h
h
i
g
h
c
o
m
p
a
r
e
d
w
i
t
h
l
o
w
v
a
r
i
a
b
i
l
i
t
y
s
c
o
r
e
s
w
a
s
5
6
±
6
%
v
e
r
s
u
s
4
3
±
5
%
(
p
=
0
.
0
0
1
)
.
M
o
r
t
a
l
i
t
y
i
n
t
h
e
h
i
g
h
l
y
v
a
r
i
a
b
l
e
g
r
o
u
p
w
a
s
t
w
i
c
e
t
h
a
t
o
f
t
h
e
l
e
s
s
v
a
r
i
a
b
l
e
g
r
o
u
p
(
5
0
v
s
.
2
2
%
,
p
=
0
.
0
4
1
)
H
i
g
h
g
l
u
c
o
s
e
v
a
r
i
a
b
i
l
i
t
y
(
d
e
ﬁ
n
e
d
a
s
[
5
0
%
o
f
v
a
l
u
e
s
o
u
t
s
i
d
e
t
h
e
8
0
–
1
1
0
r
a
n
g
e
)
i
s
a
s
s
o
c
i
a
t
e
d
w
i
t
h
i
n
c
r
e
a
s
e
d
m
o
r
t
a
l
i
t
y
D
o
s
s
e
t
t
e
t
a
l
.
[
2
8
]
,
2
0
0
8
,
U
S
8
5
8
v
e
n
t
i
l
a
t
e
d
s
u
r
g
i
c
a
l
a
n
d
t
r
a
u
m
a
p
a
t
i
e
n
t
s
w
i
t
h
a
t
l
e
a
s
t
5
m
e
a
s
u
r
e
m
e
n
t
s
,
s
u
r
g
i
c
a
l
a
n
d
t
r
a
u
m
a
I
C
U
B
l
o
o
d
g
l
u
c
o
s
e
p
e
r
c
e
n
t
i
l
e
T
r
i
a
n
g
u
l
a
r
i
n
d
e
x
S
u
c
c
e
s
s
i
v
e
c
h
a
n
g
e
i
n
B
G
L
S
D
H
o
s
p
i
t
a
l
m
o
r
t
a
l
i
t
y
P
h
y
s
i
c
i
a
n
/
n
u
r
s
e
d
r
i
v
e
n
W
i
t
h
p
r
o
t
o
c
o
l
a
n
d
C
D
S
S
T
R
8
0
–
1
1
0
M
1
–
2
h
U
n
i
v
a
r
i
a
t
e
a
n
a
l
y
s
i
s
a
n
d
m
u
l
t
i
v
a
r
i
a
t
e
l
o
g
i
s
t
i
c
r
e
g
r
e
s
s
i
o
n
u
s
e
d
t
o
c
o
m
p
a
r
e
c
o
m
b
i
n
a
t
i
o
n
o
f
p
e
r
c
e
n
t
i
l
e
s
.
P
a
t
i
e
n
t
s
w
e
r
e
a
s
s
i
g
n
e
d
t
o
g
r
o
u
p
b
a
s
e
d
o
n
B
G
L
p
e
r
c
e
n
t
i
l
e
S
D
f
o
r
t
h
o
s
e
w
i
t
h
s
i
m
i
l
a
r
m
e
a
n
B
G
L
a
n
d
p
e
r
c
e
n
t
i
l
e
v
a
l
u
e
s
o
f
B
G
L
d
i
d
n
o
t
s
i
g
n
i
ﬁ
c
a
n
t
l
y
d
i
f
f
e
r
b
e
t
w
e
e
n
s
u
r
v
i
v
a
l
s
t
a
t
u
s
g
r
o
u
p
s
.
T
h
e
m
e
a
n
l
a
r
g
e
s
t
s
u
c
c
e
s
s
i
v
e
i
n
c
r
e
a
s
e
s
(
a
n
d
d
e
c
r
e
a
s
e
)
i
n
B
G
L
w
e
r
e
5
4
m
g
/
d
l
(
a
n
d
-
7
1
m
g
/
d
l
)
f
o
r
s
u
r
v
i
v
o
r
s
a
n
d
7
0
m
g
/
d
l
(
a
n
d
-
7
9
m
g
/
d
l
)
f
o
r
n
o
n
s
u
r
v
i
v
o
r
s
,
w
i
t
h
p
=
0
.
0
0
1
(
a
n
d
p
=
0
.
0
2
)
.
T
h
e
m
a
x
i
m
u
m
a
b
s
o
l
u
t
e
c
h
a
n
g
e
w
a
s
7
6
m
g
/
d
l
v
e
r
s
u
s
9
4
m
g
/
d
l
(
p
=
.
0
0
5
)
.
T
h
e
t
r
i
a
n
g
u
l
a
r
i
n
d
e
x
f
o
r
a
l
l
m
e
a
s
u
r
e
s
w
a
s
s
t
a
t
i
s
t
i
c
a
l
l
y
d
i
f
f
e
r
e
n
t
b
e
t
w
e
e
n
t
h
e
t
w
o
g
r
o
u
p
s
I
n
c
r
e
a
s
e
d
b
l
o
o
d
g
l
u
c
o
s
e
v
a
r
i
a
b
i
l
i
t
y
i
n
t
e
r
m
s
o
f
t
r
i
a
n
g
u
l
a
r
i
n
d
e
x
a
n
d
s
u
c
c
e
s
s
i
v
e
c
h
a
n
g
e
i
n
B
G
L
i
s
a
s
s
o
c
i
a
t
e
d
w
i
t
h
m
o
r
t
a
l
i
t
y
H
i
r
s
h
b
e
r
g
e
t
a
l
.
[
2
9
]
,
2
0
0
8
,
U
S
8
6
3
n
o
n
-
d
i
a
b
e
t
i
c
p
a
t
i
e
n
t
s
,
h
y
p
o
g
l
y
c
e
m
i
a
e
v
e
n
t
s
h
o
u
l
d
n
o
t
b
e
r
e
a
s
o
n
f
o
r
I
C
U
a
d
m
i
s
s
i
o
n
,
w
i
t
h
o
u
t
i
n
s
u
l
i
n
a
d
m
i
n
i
s
t
r
a
t
i
o
n
,
[
2
4
h
s
t
a
y
,
B
1
8
y
e
a
r
s
,
2
6
-
b
e
d
p
e
d
i
a
t
r
i
c
I
C
U
H
y
p
e
r
–
h
y
p
o
M
o
r
t
a
l
i
t
y
W
i
t
h
o
u
t
p
r
o
t
o
c
o
l
U
n
i
v
a
r
i
a
t
e
a
n
a
l
y
s
i
s
i
n
d
i
f
f
e
r
e
n
t
m
e
a
n
B
G
L
g
r
o
u
p
s
(
\
6
0
,
6
0
–
1
5
0
,
[
1
5
0
)
.
M
u
l
t
i
v
a
r
i
a
t
e
l
o
g
i
s
t
i
c
r
e
g
r
e
s
s
i
o
n
a
d
j
u
s
t
e
d
f
o
r
P
R
I
S
M
I
I
I
,
m
e
d
i
c
a
l
d
i
a
g
n
o
s
i
s
g
r
o
u
p
B
G
v
a
r
i
a
b
i
l
i
t
y
o
c
c
u
r
r
e
d
i
n
6
.
8
%
o
f
a
l
l
p
a
t
i
e
n
t
s
.
I
t
w
a
s
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
ﬁ
c
a
n
t
l
y
a
s
s
o
c
i
a
t
e
d
i
n
u
n
i
v
a
r
i
a
t
e
a
n
d
m
u
l
t
i
v
a
r
i
a
t
e
a
n
a
l
y
s
i
s
w
i
t
h
i
n
c
r
e
a
s
e
d
m
o
r
t
a
l
i
t
y
(
O
R
6
3
.
6
;
9
5
%
C
I
7
.
8
–
5
1
2
a
n
d
O
R
4
0
.
5
;
9
5
%
C
I
4
.
6
–
3
5
8
.
7
)
B
G
v
a
r
i
a
b
i
l
i
t
y
i
n
t
h
e
m
u
l
t
i
v
a
r
i
a
t
e
a
n
a
l
y
s
i
s
w
a
s
a
s
s
o
c
i
a
t
e
d
w
i
t
h
i
n
c
r
e
a
s
e
d
m
o
r
t
a
l
i
t
y
587T
a
b
l
e
1
c
o
n
t
i
n
u
e
d
R
e
f
e
r
e
n
c
e
P
a
t
i
e
n
t
p
o
p
u
l
a
t
i
o
n
a
n
d
l
o
c
a
t
i
o
n
(
s
)
V
a
r
i
a
b
i
l
i
t
y
i
n
d
i
c
a
t
o
r
(
s
)
O
u
t
c
o
m
e
m
e
a
s
u
r
e
G
l
u
c
o
s
e
r
e
g
u
l
a
t
i
o
n
S
t
a
t
i
s
t
i
c
a
l
a
p
p
r
o
a
c
h
R
e
s
u
l
t
s
R
e
p
o
r
t
e
d
c
o
n
c
l
u
s
i
o
n
K
r
i
n
s
l
e
y
[
1
9
]
,
2
0
0
8
,
U
S
3
,
2
5
2
a
d
u
l
t
p
a
t
i
e
n
t
s
,
1
4
-
b
e
d
m
i
x
e
d
m
e
d
i
c
a
l
/
s
u
r
g
i
c
a
l
I
C
U
S
D
H
o
s
p
i
t
a
l
m
o
r
t
a
l
i
t
y
F
i
n
g
e
r
c
a
p
i
l
l
a
r
y
s
a
m
p
l
i
n
g
?
p
l
a
s
m
a
g
l
u
c
o
s
e
(
t
e
s
t
e
d
i
n
c
e
n
t
r
a
l
l
a
b
)
N
u
r
s
e
d
r
i
v
e
n
N
o
n
-
I
I
T
(
b
e
f
o
r
e
2
0
0
3
)
a
n
d
I
I
T
p
r
o
t
o
c
o
l
(
f
r
o
m
2
0
0
5
)
T
R
8
0
–
1
4
0
a
n
d
8
0
–
1
2
5
U
n
i
v
a
r
i
a
t
e
a
n
a
l
y
s
i
s
i
n
d
i
f
f
e
r
e
n
t
m
e
a
n
B
G
L
g
r
o
u
p
s
(
7
0
–
9
9
,
1
0
0
–
1
1
9
,
1
2
0
–
1
3
9
,
1
4
0
–
1
7
9
,
1
8
0
?
)
.
M
u
l
t
i
v
a
r
i
a
t
e
l
o
g
i
s
t
i
c
r
e
g
r
e
s
s
i
o
n
a
d
j
u
s
t
e
d
f
o
r
a
g
e
,
A
P
A
C
H
E
I
I
w
i
t
h
o
u
t
t
h
e
a
g
e
c
o
m
p
o
n
e
n
t
,
M
V
,
S
D
o
f
m
e
a
n
B
G
L
,
d
i
a
b
e
t
i
c
s
t
a
t
u
s
,
t
r
e
a
t
m
e
n
t
e
r
a
(
n
o
n
-
I
I
T
a
n
d
I
I
T
)
,
a
n
d
d
i
f
f
e
r
e
n
t
g
r
o
u
p
s
o
f
m
e
a
n
B
G
L
(
7
0
–
9
9
,
1
0
0
–
1
1
9
,
1
2
0
–
1
3
9
)
Q
u
a
r
t
i
l
e
w
i
t
h
h
i
g
h
e
s
t
v
a
r
i
a
b
i
l
i
t
y
h
a
d
5
-
,
3
-
,
2
-
,
a
n
d
1
.
7
-
f
o
l
d
i
n
c
r
e
a
s
e
i
n
m
o
r
t
a
l
i
t
y
v
e
r
s
u
s
t
h
e
l
o
w
e
s
t
q
u
a
r
t
i
l
e
f
o
r
p
a
t
i
e
n
t
s
w
i
t
h
m
e
a
n
B
G
L
b
e
t
w
e
e
n
7
0
–
9
9
,
1
0
0
–
1
1
9
,
1
2
0
–
1
3
9
,
a
n
d
1
4
0
–
1
7
9
m
g
/
d
l
(
a
l
l
p
B
0
.
0
1
)
.
M
u
l
t
i
v
a
r
i
a
b
l
e
a
n
a
l
y
s
i
s
d
e
m
o
n
s
t
r
a
t
e
d
t
h
a
t
G
V
i
n
d
e
p
e
n
d
e
n
t
l
y
c
o
n
f
e
r
r
e
d
i
n
c
r
e
a
s
e
d
r
i
s
k
o
f
m
o
r
t
a
l
i
t
y
a
m
o
n
g
p
a
t
i
e
n
t
s
w
i
t
h
m
e
a
n
B
G
L
u
p
t
i
l
1
3
9
m
g
/
d
l
(
i
n
a
l
l
c
a
s
e
s
p
B
0
.
0
5
)
I
n
c
r
e
a
s
i
n
g
g
l
y
c
e
m
i
c
v
a
r
i
a
b
i
l
i
t
y
c
o
n
f
e
r
r
e
d
a
s
t
r
o
n
g
i
n
d
e
p
e
n
d
e
n
t
r
i
s
k
o
f
m
o
r
t
a
l
i
t
y
W
a
e
s
c
h
l
e
e
t
a
l
.
[
3
0
]
,
2
0
0
8
,
G
e
r
m
a
n
y
1
9
1
p
a
t
i
e
n
t
s
w
i
t
h
s
e
p
s
i
s
,
s
e
v
e
r
e
s
e
p
s
i
s
o
r
s
e
p
t
i
c
s
h
o
c
k
,
4
2
-
b
e
d
I
C
U
S
D
I
C
U
a
n
d
h
o
s
p
i
t
a
l
m
o
r
t
a
l
i
t
y
F
i
n
g
e
r
c
a
p
i
l
l
a
r
y
s
a
m
p
l
i
n
g
N
u
r
s
e
d
r
i
v
e
n
W
i
t
h
t
w
o
d
i
f
f
e
r
e
n
t
p
r
o
t
o
c
o
l
s
T
R
8
0
–
1
4
0
M
3
0
m
i
n
–
3
h
U
n
i
v
a
r
i
a
t
e
a
n
a
l
y
s
i
s
a
n
d
m
u
l
t
i
v
a
r
i
a
t
e
l
o
g
i
s
t
i
c
r
e
g
r
e
s
s
i
o
n
a
d
j
u
s
t
e
d
f
o
r
r
a
t
e
o
f
s
e
v
e
r
e
h
y
p
o
g
l
y
c
e
m
i
a
(
B
4
0
)
,
m
e
d
i
a
n
S
D
,
p
r
e
s
e
n
t
o
f
I
I
T
p
r
o
t
o
c
o
l
M
u
l
t
i
v
a
r
i
a
t
e
a
n
a
l
y
s
e
s
s
h
o
w
e
d
a
s
i
g
n
i
ﬁ
c
a
n
t
a
s
s
o
c
i
a
t
i
o
n
o
f
S
D
l
e
v
e
l
s
w
i
t
h
c
r
i
t
i
c
a
l
h
y
p
o
g
l
y
c
e
m
i
a
e
s
p
e
c
i
a
l
l
y
f
o
r
p
a
t
i
e
n
t
s
i
n
s
e
p
t
i
c
s
h
o
c
k
(
p
=
0
.
0
1
9
7
)
.
I
n
a
d
d
i
t
i
o
n
,
S
D
l
e
v
e
l
s
a
b
o
v
e
2
0
m
g
/
d
l
w
e
r
e
a
s
s
o
c
i
a
t
e
d
w
i
t
h
a
s
i
g
n
i
ﬁ
c
a
n
t
l
y
h
i
g
h
e
r
m
o
r
t
a
l
i
t
y
r
a
t
e
r
e
l
a
t
i
v
e
t
o
t
h
o
s
e
w
i
t
h
S
D
l
e
v
e
l
s
b
e
l
o
w
2
0
m
g
/
d
l
(
2
4
v
s
.
2
.
5
%
,
p
=
0
.
0
1
9
5
)
S
i
g
n
i
ﬁ
c
a
n
t
a
s
s
o
c
i
a
t
i
o
n
o
f
S
D
l
e
v
e
l
s
w
i
t
h
c
r
i
t
i
c
a
l
h
y
p
o
g
l
y
c
e
m
i
a
w
a
s
s
h
o
w
n
.
I
n
a
d
d
i
t
i
o
n
S
D
l
e
v
e
l
s
w
e
r
e
a
s
s
o
c
i
a
t
e
d
w
i
t
h
m
o
r
t
a
l
i
t
y
r
a
t
e
A
l
i
e
t
a
l
.
[
1
5
]
,
2
0
0
8
,
U
S
1
,
2
4
6
s
e
p
t
i
c
p
a
t
i
e
n
t
s
h
o
s
p
i
t
a
l
i
z
e
d
f
o
r
m
o
r
e
t
h
a
n
1
d
a
y
S
D
M
A
G
E
G
L
I
H
o
s
p
i
t
a
l
m
o
r
t
a
l
i
t
y
W
h
o
l
e
b
l
o
o
d
g
l
u
c
o
s
e
P
l
a
s
m
a
g
l
u
c
o
s
e
(
t
e
s
t
e
d
i
n
c
e
n
t
r
a
l
l
a
b
)
M
u
l
t
i
v
a
r
i
a
b
l
e
l
o
g
i
s
t
i
c
r
e
g
r
e
s
s
i
o
n
a
d
j
u
s
t
e
d
f
o
r
n
u
m
b
e
r
o
f
o
r
g
a
n
f
a
i
l
u
r
e
,
o
c
c
u
r
r
e
n
c
e
o
f
h
y
p
o
g
l
y
c
e
m
i
a
,
i
n
s
u
l
i
n
a
d
m
i
n
i
s
t
r
a
t
i
o
n
,
f
r
e
q
u
e
n
c
y
o
f
g
l
u
c
o
s
e
m
o
n
i
t
o
r
i
n
g
a
n
d
c
a
p
i
l
l
a
r
y
t
e
s
t
i
n
g
B
e
c
a
u
s
e
o
f
s
i
g
n
i
ﬁ
c
a
n
t
i
n
t
e
r
a
c
t
i
o
n
b
e
t
w
e
e
n
t
h
e
g
l
u
c
o
s
e
-
r
e
l
a
t
e
d
m
e
a
s
u
r
e
s
,
t
h
e
s
u
b
j
e
c
t
s
w
e
r
e
d
i
v
i
d
e
d
i
n
t
o
f
o
u
r
g
r
o
u
p
s
(
m
e
d
i
a
n
a
n
d
I
Q
R
)
b
a
s
e
d
o
n
G
L
I
a
n
d
m
e
a
n
B
G
L
M
A
G
E
,
S
D
,
a
n
d
G
L
I
w
e
r
e
a
s
s
o
c
i
a
t
e
d
w
i
t
h
h
o
s
p
i
t
a
l
m
o
r
t
a
l
i
t
y
(
c
r
u
d
e
O
R
1
.
1
2
,
1
.
1
6
,
1
.
2
5
,
p
\
0
.
0
0
1
i
n
a
l
l
c
a
s
e
s
)
a
n
d
,
G
L
I
h
a
d
t
h
e
b
e
s
t
A
U
C
(
5
9
,
.
6
2
,
.
6
7
,
p
\
0
.
0
0
1
)
.
G
L
I
w
a
s
n
o
t
i
n
d
e
p
e
n
d
e
n
t
l
y
a
s
s
o
c
i
a
t
e
d
w
i
t
h
m
o
r
t
a
l
i
t
y
f
o
r
t
h
o
s
e
w
i
t
h
m
e
a
n
B
G
L
[
m
e
d
i
a
n
.
S
u
b
j
e
c
t
s
w
i
t
h
i
n
c
r
e
a
s
e
d
G
L
I
,
b
u
t
l
o
w
e
r
m
e
a
n
B
G
L
h
a
d
a
l
m
o
s
t
5
-
f
o
l
d
o
d
d
s
o
f
h
o
s
p
i
t
a
l
m
o
r
t
a
l
i
t
y
t
h
a
n
t
h
o
s
e
w
i
t
h
l
o
w
e
r
G
L
I
(
O
R
4
.
7
3
,
9
5
%
C
I
2
.
6
–
8
.
7
)
M
A
G
E
,
S
D
,
a
n
d
G
L
I
w
e
r
e
a
s
s
o
c
i
a
t
e
d
w
i
t
h
h
o
s
p
i
t
a
l
m
o
r
t
a
l
i
t
y
.
G
L
I
h
a
d
t
h
e
b
e
s
t
d
i
s
c
r
i
m
i
n
a
t
i
o
n
f
o
r
m
o
r
t
a
l
i
t
y
588T
a
b
l
e
1
c
o
n
t
i
n
u
e
d
R
e
f
e
r
e
n
c
e
P
a
t
i
e
n
t
p
o
p
u
l
a
t
i
o
n
a
n
d
l
o
c
a
t
i
o
n
(
s
)
V
a
r
i
a
b
i
l
i
t
y
i
n
d
i
c
a
t
o
r
(
s
)
O
u
t
c
o
m
e
m
e
a
s
u
r
e
G
l
u
c
o
s
e
r
e
g
u
l
a
t
i
o
n
S
t
a
t
i
s
t
i
c
a
l
a
p
p
r
o
a
c
h
R
e
s
u
l
t
s
R
e
p
o
r
t
e
d
c
o
n
c
l
u
s
i
o
n
E
g
i
e
t
a
l
.
[
3
1
]
,
2
0
0
6
A
u
s
t
r
a
l
i
a
7
,
0
4
9
p
a
t
i
e
n
t
s
D
i
a
b
e
t
e
s
d
i
a
g
n
o
s
i
s
d
a
t
a
w
a
s
a
v
a
i
l
a
b
l
e
i
n
2
o
u
t
o
f
4
I
C
U
s
,
4
s
u
r
g
i
c
a
l
/
m
e
d
i
c
a
l
m
i
x
e
d
I
C
U
s
S
D
R
e
l
a
t
i
v
e
v
a
r
i
a
b
i
l
i
t
y
I
C
U
a
n
d
h
o
s
p
i
t
a
l
m
o
r
t
a
l
i
t
y
W
h
o
l
e
b
l
o
o
d
s
a
m
p
l
i
n
g
N
u
r
s
e
d
r
i
v
e
n
W
i
t
h
o
u
t
p
r
o
t
o
c
o
l
T
R
1
0
8
–
1
8
0
U
n
i
v
a
r
i
a
t
e
a
n
a
l
y
s
i
s
a
n
d
m
u
l
t
i
v
a
r
i
a
t
e
l
o
g
i
s
t
i
c
r
e
g
r
e
s
s
i
o
n
a
d
j
u
s
t
e
d
f
o
r
I
C
U
l
o
c
a
t
i
o
n
,
a
g
e
,
A
P
A
C
H
E
I
I
,
c
a
t
e
g
o
r
y
o
f
I
C
U
a
d
m
i
s
s
i
o
n
,
s
u
r
g
i
c
a
l
/
m
e
d
i
c
a
l
a
d
m
i
s
s
i
o
n
,
S
D
,
m
e
a
n
B
G
L
,
m
a
x
B
G
L
,
a
d
m
i
s
s
i
o
n
B
G
L
,
M
V
,
a
n
d
d
i
a
b
e
t
e
s
s
t
a
t
u
s
T
h
e
m
e
a
n
±
S
D
o
f
S
D
w
a
s
3
0
±
2
3
v
e
r
s
u
s
4
1
±
2
9
m
g
i
n
s
u
r
v
i
v
o
r
s
v
e
r
s
u
s
n
o
n
s
u
r
v
i
v
o
r
s
(
p
\
0
.
0
0
1
)
.
B
o
t
h
m
e
a
n
a
n
d
S
D
o
f
b
l
o
o
d
g
l
u
c
o
s
e
w
e
r
e
s
i
g
n
i
ﬁ
c
a
n
t
l
y
a
s
s
o
c
i
a
t
e
d
w
i
t
h
I
C
U
m
o
r
t
a
l
i
t
y
[
p
\
0
.
0
0
1
;
a
d
j
u
s
t
e
d
O
R
(
p
e
r
1
8
m
g
)
1
.
2
3
a
n
d
1
.
2
7
]
a
n
d
h
o
s
p
i
t
a
l
m
o
r
t
a
l
i
t
y
[
p
\
0
.
0
0
1
a
n
d
p
=
0
.
0
1
3
;
O
R
(
p
e
r
1
8
m
g
)
1
.
2
1
a
n
d
1
.
1
8
]
T
h
e
S
D
o
f
B
G
L
s
i
s
a
s
i
g
n
i
ﬁ
c
a
n
t
i
n
d
e
p
e
n
d
e
n
t
p
r
e
d
i
c
t
o
r
o
f
I
C
U
a
n
d
h
o
s
p
i
t
a
l
m
o
r
t
a
l
i
t
y
W
i
n
t
e
r
g
e
r
s
t
e
t
a
l
.
[
3
2
]
,
2
0
0
6
,
U
S
1
,
0
9
4
\
2
2
y
e
a
r
s
o
l
d
n
o
n
-
d
i
a
b
e
t
i
c
p
a
t
i
e
n
t
s
,
p
e
d
i
a
t
r
i
c
I
C
U
G
l
u
c
o
s
e
v
a
r
i
a
b
i
l
i
t
y
i
n
d
e
x
H
o
s
p
i
t
a
l
m
o
r
t
a
l
i
t
y
W
h
o
l
e
b
l
o
o
d
g
l
u
c
o
s
e
P
l
a
s
m
a
g
l
u
c
o
s
e
(
t
e
s
t
e
d
i
n
c
e
n
t
r
a
l
l
a
b
)
U
n
i
v
a
r
i
a
t
e
a
n
a
l
y
s
i
s
a
n
d
m
u
l
t
i
v
a
r
i
a
b
l
e
l
o
g
i
s
t
i
c
r
e
g
r
e
s
s
i
o
n
a
d
j
u
s
t
e
d
f
o
r
g
l
u
c
o
s
e
v
a
r
i
a
b
i
l
i
t
y
,
m
i
n
i
m
a
l
B
G
L
,
a
n
d
m
a
x
i
m
a
l
B
G
L
M
o
r
t
a
l
i
t
y
r
a
t
e
w
i
t
h
h
i
g
h
e
s
t
v
e
r
s
u
s
l
o
w
e
s
t
q
u
i
n
t
i
l
e
w
a
s
1
5
.
1
v
e
r
s
u
s
1
.
3
%
(
p
\
.
0
0
0
1
)
.
G
l
u
c
o
s
e
v
a
r
i
a
b
i
l
i
t
y
,
m
i
n
i
m
a
l
g
l
u
c
o
s
e
l
e
v
e
l
,
a
n
d
m
a
x
i
m
a
l
g
l
u
c
o
s
e
l
e
v
e
l
(
a
l
l
w
i
t
h
p
B
0
.
0
5
)
e
a
c
h
h
a
d
a
n
i
n
d
e
p
e
n
d
e
n
t
r
e
l
a
t
i
o
n
s
h
i
p
w
i
t
h
d
e
a
t
h
G
l
u
c
o
s
e
v
a
r
i
a
b
i
l
i
t
y
w
a
s
a
s
s
o
c
i
a
t
e
d
w
i
t
h
m
o
r
t
a
l
i
t
y
r
a
t
e
E
x
c
e
p
t
f
o
r
r
e
f
e
r
e
n
c
e
[
3
0
]
,
w
h
i
c
h
r
e
p
o
r
t
e
d
o
n
a
p
r
o
s
p
e
c
t
i
v
e
o
b
s
e
r
v
a
t
i
o
n
a
l
c
o
h
o
r
t
,
a
l
l
s
t
u
d
i
e
s
p
e
r
t
a
i
n
e
d
t
o
r
e
t
r
o
s
p
e
c
t
i
v
e
o
b
s
e
r
v
a
t
i
o
n
a
l
c
o
h
o
r
t
s
.
U
n
i
t
o
f
a
l
l
B
G
L
t
h
r
e
s
h
o
l
d
s
i
s
m
g
/
d
l
B
G
L
b
l
o
o
d
g
l
u
c
o
s
e
l
e
v
e
l
,
S
D
s
t
a
n
d
a
r
d
d
e
v
i
a
t
i
o
n
,
G
L
I
g
l
y
c
e
m
i
c
l
a
b
i
l
i
t
y
i
n
d
e
x
,
M
A
G
m
e
a
n
a
b
s
o
l
u
t
e
g
l
u
c
o
s
e
,
M
A
G
E
m
e
a
n
a
m
p
l
i
t
u
d
e
o
f
g
l
y
c
e
m
i
c
e
x
c
u
r
s
i
o
n
s
,
C
I
c
o
n
ﬁ
d
e
n
c
e
i
n
t
e
r
v
a
l
,
I
C
U
i
n
t
e
n
s
i
v
e
c
a
r
e
u
n
i
t
,
I
I
T
i
n
t
e
n
s
i
v
e
i
n
s
u
l
i
n
t
h
e
r
a
p
y
,
L
O
S
l
e
n
g
t
h
o
f
s
t
a
y
,
M
m
o
n
i
t
o
r
i
n
g
,
M
V
m
e
c
h
a
n
i
c
a
l
v
e
n
t
i
l
a
t
i
o
n
,
O
R
o
d
d
s
r
a
t
i
o
,
T
R
t
a
r
g
e
t
r
a
n
g
e
,
A
U
C
a
r
e
a
u
n
d
e
r
t
h
e
c
u
r
v
e
,
I
Q
R
i
n
t
e
r
q
u
a
r
t
i
l
e
r
a
n
g
e
,
G
V
g
l
y
c
e
m
i
c
v
a
r
i
a
b
i
l
i
t
y
,
C
D
S
S
c
o
m
p
u
t
e
r
i
z
e
d
d
e
c
i
s
i
o
n
-
s
u
p
p
o
r
t
s
y
s
t
e
m
589based on normality assumptions may then be ﬂawed as
they, e.g., would imply the existence of negative BGLs
below a number of standard deviations from the mean.
The variability itself in exposure to hyper- or hypogly-
cemia may as well not be symmetric about a mean value.
Application of normal statistics to lognormal or skewed
distributions can hence yield misleading results.
There should be an agreement on which subset of
indicators should be used and reported in future studies but
this requires a better understanding of what the indicators
intend to measure. This is particularly relevant because the
act of measuring BGL is primarily directed to inform
future BGL regulation decisions, so BGL measurements
would tend to cluster around changes. Some changes are
beneﬁcial because they steer BGL towards a target value,
others are not. If indicators do not take the direction of a
change into account, as is the case, e.g., for the mean
absolute glucose (MAG), mean amplitude of glycemic
excursions (MAGE), and glycemic lability index (GLI),
then they are likely to be sensitive to the sampling fre-
quency of the blood glucose regulation policy and there is
a possibility that they, indirectly, also reﬂect severity of
illness. MAG, MAGE, and GLI take order of measure-
ments into account but only MAG and GLI consider the
time that elapsed between measurements. SD, hypogly-
cemia, hyperglycemia, mean daily d BGL, and successive
change do not take order and timing of measurements into
account. Both hypo- and hyperglycemia also depend on
the deﬁned threshold. It is unclear which characteristics
are responsible for picking up on the variability with the
true deleterious biological effect and which are not. To the
best of our knowledge there is no study that measured
correlation among measures of variability. This merits
future research and it can shed light on what is missed
when using one measure rather than another.
Recently we suggested that the association of measures
such as MAG with mortality may well be blurred by the
frequency of observations, and in turn by whether the
patients belong to a TGC cohort or not [17]. Three studies
[16, 18, 19] investigated the association between mortality
and variability in a TGC and/or a control group as well as
ina pooledcohort.In contrast tothe Leuven study[16],the
SPRINT study [18] showed no signiﬁcant association
between variability and mortality in the SPRINT or TGC
arm. Krinsley et al. [19] showed that treatment in the TGC
era was negatively correlated to SD. TGC might in this
sense be perceived as statistically ‘‘decoupling’’ metrics of
variability from mortality within a TGC cohort. Further
similar analyses are recommended. In addition, one should
realize that there are two statistical ways to view associ-
ation: testing and estimation. Testing pretends that the
answer to the association question is yes or no. In contrast,
Table 2 List of applied blood glucose variability indicators
Variability indicators Deﬁnition Ref.
Standard deviation SD of BGL measurement for each patient during the complete stay in
ICU or during the ﬁrst 24 h after admission [31]
[13, 15, 16, 19, 30, 31]
Both hypo and hyper Deﬁned for a patient as any patient as the presence of both
hyperglycemia ([150 [29],[180 [25], or[216 mg/dl [26]) and
hypoglycemia (\60 [29],\72 [25], or\81 mg/dl [26]) during the
complete stay in ICU [25], [29], or during the ﬁrst 24 h after ICU
admission [26]
[25, 26], 29]
Blood glucose percentile Individual variable ranked, with various percentiles (P50, P95, etc.) [28]
Glucose variability index Mean of absolute difference of sequential BGLs divided by the
difference in BGL collection time
[32]
GLI Squared difference between consecutive BGLs per unit of actual time
between those samples
[15]
MAG Mean absolute glucose change per patient per hour [13]
MAGE Mean of absolute values of any delta BGL (consecutive values) that are
[1 SD of the entire set of BGLs
[15]
Mean daily d BGL Mean of daily difference between minimum and maximum BGL [16]
Relative variability Coefﬁcient of variability (GluCV = GluSD 9 100/GluAve) [31]
Successive change Successive change in BGL calculated by determining the difference in
two consecutive BGLs—the largest successive increase, decrease, and
absolute value were calculated for each patient (regardless of interval
between measures)
[28]
Percent excursion above
and below target
Percent excursion (as fraction of the whole) above and below BGL target
with the total number of measurements as the denominator
[27]
Triangular index Calculated by dividing the maximum sample density distribution of each
histogram for BGL (i.e., the mode) from an individual patient (on a
discrete scale with bin of 1 mg/dl) by the total number of each
measurement
[28]
BGL blood glucose level, GLI glycemic lability index, MAG mean absolute glucose, MAGE mean amplitude of glycemic excursions
590in estimation one simply attempts to quantify the strength
of the association, however weak it may be. ‘‘Proving’’ the
absence of any association is very hard, but it is easy to
quantify its strength. There is a need for new statistical
approaches, such as the Bayesian approach, that do not
rely on p values and testing, and this facilitates more
reliable meta-analysis.
A recent study [20] performed complexity analysis in
glycemia time series and showed that loss of complexity,
evaluated by detrended ﬂuctuation analysis, is associated
with higher mortality. Lack of complexity may signify
failure of regulatory systems or extreme consequences of
pathophysiological processes. It might be useful to per-
form complexity analysis, in addition to the traditional
variability analysis, in future studies.
Although the majority of studies used linear logistic
regression to adjust for confounders, different sets of
candidate confounders were used in the studies, again
hampering comparability. The choice of these candidates
should be motivated by the possible explanations of the
suspected association between glucose variability and
mortality. Egi et al. [12] state that there are at least three
possible explanations for this association. First, less glu-
cose variability could result from more attention in
medical and nursing care. Second, less glucose variability
may be associated with less severity of illness. Third,
glycemic variability might have a true deleterious bio-
logical effect in critically ill patients. Hence it is
important to always control for the measurement rate per
patient (inﬂuenced by the blood glucose control protocol
and the severity of illness of the patient) as well as
severity of illness itself. Otherwise the true deleterious
biological effect will be blurred. It is hence beneﬁcial to
report on the relationship between a variability indicator
and factors that may inﬂuence it including measurement
rate (or mean interval between measurements) and
severity of illness. This was not attempted in the studies.
Aside from adjustment in the model, the assumption of
linearity between (log odds of) mortality and the indicator
and/or the confounders used was not tested when the
variables were coded as continuous. By making sure that
the assumptions hold, one gets unbiased odds ratio esti-
mates of the variables used.
The course taken in research pertaining to the associa-
tion between blood glucose variability and mortality is
reminiscent of the course taken in researching the associ-
ation between blood glucose level indicators and the
quality of the glucose regulation process. In two recent
systematic reviews we showed that many different and
even ambiguous quality indicators were used to measure
the quality of glucose regulation in these studies which
hinders synthesizing evidence [8, 21, 22]. If blood glucose
variability is to form a new target in blood glucose control,
we need to acknowledge that the term covers various types
of variability and deﬁne at this stage a uniform set of
quality indicators for it that can be used consistently and
compared in each study to avoid reporting bias. Second, if
someindicators areunambiguouslyshowntobe associated
with mortality then we need to develop an approach for
inﬂuencing them. However this is not trivial especially
because other factors, such as mean blood glucose level,
should be reckoned with. These important issues should be
addressed before conducting new clinical trials on blood
glucose variability.
Finally, glycemic metrics in TGC are typically only
linked to mortality through a host of other therapies and
factors (such as patient condition and age). Linking
mortality and glycemia may, however, simply be a
‘‘bridge too far’’ as there is no direct physiological link
between glycemia and mortality, except through a range
of intermediate physiological processes, which may or
may not tip the balance. What seems useful is to have a
metric of variability (or level) that links between glyce-
mic control and a clinical outcome that is ‘‘closer’’ to the
physiological effects of glycemia than mortality. This link
has appeared in some studies [23, 24]. Seeking metrics
that are linked more directly to negative physiological
effects merits further research.
Conclusion
The evidence about the independent association between
BGL variability and mortality is still unsettled, partly
because the term variability bears different meanings and
partly because of heterogeneity of studies, design, and
methodological and reporting limitations.
All the following considerations separately and com-
bined can beneﬁt future research. The ﬁrst is an RCT
design to investigate the effect of strategies speciﬁcally
targeting glucose variability reduction on mortality.
However, it is hard to implement an intervention that
could randomize patients to different variability cohorts,
holding other glycemic outcomes equal. It might be
acceptable to acknowledge that our understanding is
likely to come from observational data. The second is a
better understanding of what these different indicators
measure and their relationship to the perceived quality of
the BGL regulation process, the sampling frequency, and
direction of change of BGLs. The third is a uniform
indicator reference subset for glucose variability. The
fourth is a better methodology and reporting practice,
including adjustments and assumption checking pertain-
ing to confounders and reporting association measures
between severity of illness, measurement rates, and the
variability indicators.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are
credited.
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